Literature DB >> 27301938

Orosomucoid, Carotid Plaque, and Incidence of Stroke.

John Berntsson1, Gerd Östling2, Margaretha Persson2, J Gustav Smith2, Bo Hedblad2, Gunnar Engström2.   

Abstract

BACKGROUND AND
PURPOSE: Orosomucoid (α-1-acid glycoprotein) is an acute-phase protein that has been implicated in anti-inflammatory, immunomodulating, and angiogenic pathways. Orosomucoid has also been associated with coronary disease and stroke. The relationship between orosomucoid, carotid plaque, and stroke incidence were explored in this study.
METHODS: Plasma levels of orosomucoid were assessed in 4285 subjects (39.8% men; mean age 57.5±5.9 years) without cardiovascular disease, who participated in the Malmö Diet and Cancer Study, between 1991 and 1994. The right carotid artery was examined for plaque using B-mode ultrasound examination. Incidence of stroke was followed up during a median follow-up time of 17.7 years.
RESULTS: Carotid plaque was present in 43.5% at baseline. Orosomucoid was significantly higher in subjects with carotid plaque (mean±SD: 0.72±0.22 versus 0.69±0.20 g/L; P<0.001). A total of 234 subjects were diagnosed with ischemic stroke during follow-up. Orosomucoid was associated with ischemic stroke after adjustment for risk factors, with hazard ratio 1.48 (95% confidence interval, 1.02-2.16) comparing the third versus first tertile. In subjects with plaque and belonging to the top tertile of orosomucoid, the hazard ratio was 2.07 (95% confidence interval, 1.38-3.11) compared with those without plaque and with orosomucoid in the first and second tertiles, after adjustment for C-reactive protein and other risk factors.
CONCLUSIONS: Elevated levels of orosomucoid are associated with increased occurrence of carotid plaque and increased incidence of ischemic stroke. The combination of high orosomucoid and carotid plaque substantially increase the risk of stroke.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  acute-phase reaction; carotid artery disease; cytokines; risk factor; stroke

Mesh:

Substances:

Year:  2016        PMID: 27301938     DOI: 10.1161/STROKEAHA.116.013374

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  GlycA: A New Biomarker for Systemic Inflammation and Cardiovascular Disease (CVD) Risk Assessment.

Authors:  Rami A Ballout; Alan T Remaley
Journal:  J Lab Precis Med       Date:  2020-04-20

2.  A point-of-care assay for alpha-1-acid glycoprotein as a diagnostic tool for rapid, mobile-based determination of inflammation.

Authors:  Bryan M Gannon; Marshall J Glesby; Julia L Finkelstein; Tony Raj; David Erickson; Saurabh Mehta
Journal:  Curr Res Biotechnol       Date:  2019-10-25

3.  Different glycoforms of alpha-1-acid glycoprotein contribute to its functional alterations in platelets and neutrophils.

Authors:  Mosale Seetharam Sumanth; Shancy P Jacob; Kandahalli Venkataranganayaka Abhilasha; Bhanu Kanth Manne; Venkatesha Basrur; Sylvain Lehoux; Robert A Campbell; Christian C Yost; Thomas M McIntyre; Richard D Cummings; Andrew S Weyrich; Matthew T Rondina; Gopal K Marathe
Journal:  J Leukoc Biol       Date:  2020-10-18       Impact factor: 4.962

4.  Estrogen weakens muscle endurance via estrogen receptor-p38 MAPK-mediated orosomucoid (ORM) suppression.

Authors:  Yang Sun; Zhen Qin; Jing-Jing Wan; Peng-Yuan Wang; Yi-Li Yang; Jian-Guang Yu; Bo-Han Hu; Ding-Feng Su; Zhu-Min Luo; Xia Liu
Journal:  Exp Mol Med       Date:  2018-03-30       Impact factor: 8.718

5.  Proteins Involved in the Induction of Procoagulant Activity and Autoimmune Response in Patients With Primary Antiphospholipid Syndrome.

Authors:  Débora Medeiros Araújo; Carlos Ewerton Maia Rodrigues; Nidyedja Goyanna Gomes Gonçalves; Carlos Nobre Rabelo-Júnior; Marina Duarte Pinto Lobo; Renato de Azevedo Moreira; Ana Cristina de Oliveira Monteiro-Moreira
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk.

Authors:  Sonia Lopez; Angel Martinez-Perez; Alba Rodriguez-Rius; Ana Viñuela; Andrew A Brown; Laura Martin-Fernandez; Noelia Vilalta; Marc Arús; Nikolaos I Panousis; Alfonso Buil; Maria Sabater-Lleal; Juan Carlos Souto; Emmanouil T Dermitzakis; Jose Manuel Soria
Journal:  Thromb Haemost       Date:  2022-03-10       Impact factor: 6.681

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.